Especifique uma ação ou criptomoeda na barra de pesquisa para obter um resumo
Carna Biosciences Inc
4572Carna Biosciences, Inc., a clinical-stage biopharmaceutical company, discovers and develops drug therapies to treat unmet medical needs in Japan. Its products include kinase proteins, substrates, kinase protein assay kits, and stable cell lines, as well as biotinylated kinases. The company also offers profiling, NanoBRET TE intracellular kinase cell-based assay, protein detection and interaction, live-cell kinase assay, and tyrosine kinase cell-based assay services. It also focuses on developing products for the treatment of various diseases, such as AS-0141, an orally bioavailable small molecule inhibitor of CDC7 kinase that is in preclinical trials to treat cancer; AS-0871, a small molecule drug for inflammatory and immune disorders, which is in Phase 1 clinical trials; and AS-1763, an orally bioavailable and non-covalent inhibitor for the treatment of chronic lymphocytic leukemia and other B cell malignancies that is in preclinical trials. The company has collaborations with Johnson & Johnson, Sierra Oncology, Sumitomo Dainippon Pharma, Gilead Sciences, and BioNova Pharmaceuticals. Carna Biosciences, Inc. was incorporated in 2003 and is based in Kobe, Japan. Address: BMA, 1-5-5 Minatojima-Minamimachi, Kobe, Japan, 650-0047
Analytics
Preço Alvo de Wall Street
529 447.15 JPYRácio P/E
–Rendimento de dividendos
–Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Figuras chave 4572
Análise de Dividendos 4572
Crescimento de dividendos em 5 anos
–Crescimento contínuo
–Taxa de pagamento em média de 5 anos
–Histórico de Dividendos 4572
Avaliação de ações 4572
Relatório 4572
Acompanhe as principais métricas de cada ação em um só lugar, sem complicações
Inscreva-se no premiumResultados | 2019 | Dinâmica |